Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:11/7/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 25, 2014 The report ... & by Geography - Global Trends & Forecast ... with respect to market drivers, opportunities, and trends ... tables and 27 figures spread through 217 slides ... Global Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html ...
(Date:10/25/2014)... October 23, 2014 ViaDerma, ... pharmaceutical company devoted to bringing new products to ... 2015. , ViaDerma has developed an innovative, patent-pending ... rapid mass transfer of pharmaceutical active ingredients to ... provide immediate localized therapy. The transdermal delivery method ...
(Date:10/25/2014)... 2014 BioProcess International (BPI), a ... 2014 BioProcess International Awards. The awards celebrate the ... and technology applications that will allow the industry ... global patient base. , Winners and finalists were ... very entertaining and exciting awards dinner and ceremony ...
(Date:10/25/2014)... According to new market research report "Data ... Enterprise, Telecom), by Design Types (Electrical, Mechanical), and ... 3, Tier 4) - Global Forecast to 2019", ... Center Construction Market into various segments with an ... report also identifies the factors driving this market, ...
Breaking Biology Technology:Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... 15, 2011 Dr. Huda Y. Zoghbi ,  director ... (NRI) at Texas Children,s Hospital and ... 2011 Neuroscience Prize of The Peter and Patricia Gruber Foundation ... mysteries behind a number of devastating neurological disorders, including Rett ...
... June 15, 2011 Palatin Technologies, Inc. (NYSE Amex: ... for sexual dysfunction indications, announced presentation and publication of ... male sexual arousal.  The underlying study was supported by ... of the New York Presbyterian Hospital and the Weill ...
... Pharma IQ is pioneering new HTA discussion platform with launch,of ... and CER Forum , which will take an innovative form ... Health Technology Assessment has recently observed an,unprecedented global  expansion. Clinical ... UK, while clinical benefit is the main focus in France ...
Cached Biology Technology:Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 2Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 3Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 4Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 5Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 6Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal 2Health Technology Assessment Goes Online 2Health Technology Assessment Goes Online 3
(Date:10/25/2014)... , Oct.  22, 2014   MedNet Solutions ... clinical study management systems, is pleased to announce the ... two-day event – to be held in ... on track to have record attendance and promises to ... The focus of the meeting is ...
(Date:10/25/2014)... 2014 This report covers the specifics of ... in heavy pursuit of research due to its versatility ... to other RNA components. miRNA,s non-coding nature and ability ... for use as a biomarker for a variety of ... diagnostics for the advancement in therapeutic development. Furthermore there ...
(Date:10/25/2014)... 2014 A recent report, "Genetic Testing Market ... and future genetic testing market. A comprehensive introduction of ... in this report. On account of our analysis of ... strengths and challenges; forecast for genetic testing has been ... grow at a CAGR of around 9% during 2013-2018. ...
Breaking Biology News(10 mins):MedNet Solutions To Host Third Annual iMedNet User Group Meeting 2MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Genetic Testing Market Outlook 2018 2
... Boulder, Colo., USA - Two new Geology ... the Cascade arc" and "Silica gel formation during fault ... cover everything from the discovery of fossilized whale "intestinal ... of the 2010 Eyjafjallajkull volcano eruption to new findings ...
... most basic processes -- transcription of the genetic code ... a police force that controls the flow of vehicles. ... in Nature Communications , might facilitate the development ... of disorders. Transcription indeed involves a step resembling ...
... This news release is available in German . ... diarrhoea -- these symptoms could point to an infection with ... based on a syringe-like injection apparatus called injectisome. For the ... the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, ...
Cached Biology News:Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 2Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 3Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 4Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 5Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 6Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 7Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 8Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 9Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 10Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 11Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 12Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 13Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 14Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 15Gene decoding obeys road traffic rules 23-D molecular syringes 23-D molecular syringes 3
Gelatin 100 mm Culture Dishes...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
Biology Products: